J Pharmacol Sci 119, 91 -96 (2012) Myosin light-chain kinase (MLCK) is a key regulatory protein of smooth muscle contraction, non-muscle migration, and cytokinesis. MLCK is a calmodulin-dependent kinase that phosphorylates smooth muscle myosin regulatory light-chain (reviewed in ref. 1). MLCK is a multi-domain protein composed of an actin-binding domain at its N-terminal and a myosin-binding domain at its C-terminal, in addition to a kinase domain in its central core. We have been investigating the function of MLCK under conditions where the kinase activity has been deleted (reviewed in ref. 2).
that do not support a role for MLCK in cytokinesis, like in the case of C. elegans (4) , were also reported. Moreover, in our literature survey, we found no reports regarding the roles of MLCK other than its kinase activity in the cytokinesis. Therefore, in order to elucidate the functions of MLCK, we knocked-out the MLCK expression in vascular smooth muscle (VSM) cells of vertebrate origin (5, 6) . The cultured VSM cells were able to proliferate rapidly in spite of the lack of MLCK. In the above reports, we described the functions of MLCK other than its kinase activity in smooth muscle contraction, but on that occasion we did not address its role in pro liferation.
Recently, the role of the long isoform of MLCK was identified, and its regulatory role in the cytokinesis was elucidated (7) . Because our previous studies have examined only the short isoform of MLCK, we decided herein to down-regulate the expressions of both MLCK isoforms, to readdress the roles of both MLCKs in cytokinesis, by using cell proliferation as a marker.
We examined two types of vascular smooth muscle cell lines, GbaSM-4 cells of guinea pig basilar artery origin (8) and SM3 cells of rabbit aorta origin (9) . We 10) . Because the synthesized nucleotide sequences of the short and long isoforms were identical, the expression of both the isoforms could be targeted and were partially down-regulated in both GbaSM-4 and SM3 cells (Fig. 1C) . Cells transfected with MLCKsiRNA showed an increase in incorporation of 5-bromodeoxyuridine (BrdU) compared to the control cells transfected with the scrambled siRNA (Fig. 1A ) (see Materials and Methods of ref. 10 for the sequence). The incorporation of BrdU in the control GbaSM-4 cells was 21% of the total, while that of GbaSM-4 cells transfected with MLCK-siRNA increased to 65% (Fig. 1B) . Similarly to GbaSM-4 cells, BrdU incorporation to SM3 cells was 28% and 46%, respectively, for transfection with scrambled and MLCK-siRNA.
Down-Regulation of Myosin Light Chain Kinase Expression in Vascular
It was observed, however, that down-regulation of short and long MLCK isoforms by the use of synthetic siRNA transfection was not complete (Fig. 1C) and that the residual amount of MLCK isoforms expression differed from experiment to experiment, conforming our previous data (10) . Therefore, we adopted another way to establish MLCK-deficient cells line using the GbaSM-4 cell line as described in ref. 10 . In short, the lentivirus containing short hairpin RNA interference targeting guinea-pig MLCK (for the sequence, see ref. The effect of down-regulation of MLCK on the proliferation of GbaSM-4 and SM3 VSMCs. Cells were cultured in a humidified atmosphere of 5% CO2 / 95% air at 37°C and then transiently transfected with synthetic siRNAs constructed for targeting the conserved domains of short and long isoforms of MLCK in GbaSM-4 or SM3 cells by using the AMAXA nucleofector system (Lonza Group Ltd., Basel, Switzerland), as described in our previous paper (see ref. 10 for the siRNA sequences). To assess cell proliferation, we detected the proliferating cells by the 5-bromodeoxyuridine (BrdU) incorporation assay. In brief, cells were synchronized by DMEM containing 0.1% (v/v) fetal calf serum (FCS) overnight and then stimulated by the addition of DMEM containing 10% FCS with BrdU (10 μg/mL) (Roche Diagnostics, Mannheim, Germany) for 12 h. After that, the cells were fixed with 4% (v/v) paraformaldehyde for 10 min, treated with DNase I (Sigma) and exonuclease III (New England Biolabs, Beverly, MA, USA), washed with PBS, and then incubated for 30 min in blocking buffer consisting 50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 10% goat serum, 0.5 % (w/v) BSA, 0.4% Triton X-100, 50 mM L-lysine, and 0.02% (w/v) sodium azide. The cells were incubated with rat monoclonal BrdU antibody (AbD Serotec, Kidlington, UK; diluted 1:1000) for 1 h at room temperature, washed with PBS, and subsequently incubated with fluorescein-conjugated secondary antibodies and TO-PRO-3 for 1 h in the dark. A) Cells were transfected with scrambled (see ref. 10 for sequence) or MLCK specific siRNA by the AMAXA nucleofector method. The BrdU incorporation experiment was performed 48 h after transfection. After incubation with BrdU for 12 h, cells were fixed and stained with an anti-BrdU antibody. Scale bars represent 20 μm. B) The percentage of BrdU-positive cells was calculated over total TO-PRO-3-positive cells. The data were means ± S.E.M. from three experiments, n = 200 cells, Statistical significance was determined by the t-test using Sigma Stat version 3.1, **P < 0.001 vs. control. C) Lysates (20 μg) from scrambled or MLCK-specific siRNA transfected GbaSM-4 or SM3 cells were loaded to 8% SDS-PAGE followed by immunoblotting using antibody against MLCK and α-SMA.
with the virus-containing media for 14 days followed by blasticidin-resistant colony screening. The selected colony, which constitutively lacks the expression of MLCK, was thus established as MLCK-deficient cells. The expression of short MLCK and long MLCK in the cells was detected by monoclonal antibody specific for MLCK (clone K36; Sigma, St. Louis, MO, USA). The smooth muscle differentiation was checked by vascular smooth muscle cell (VSMC) marker proteins such as α-actin (α-SMA) and smooth muscle myosin heavy chain ( smMHC) by use of monoclonal antibodies specific for α-SMA (clone 1A4, Sigma) and smMHC (clone HSM-V, Sigma), respectively. We confirmed that the MLCKdeficient cells did not express the isoforms (see Fig. 4B in ref. 10) , while the expression levels of differentiated markers remained unchanged ( Fig. 2A) , suggesting that the down-regulation was specific for MLCK isoforms.
To investigate the effect of MLCK-deficiency on cell proliferation, growth curves of both control GbaSM-4 and MLCK-deficient cells were examined by MTT assay to detect live cells in a quantitative manner according to manufacturer's instructions (Sigma). The doubling time was calculated using the logarithmic portion of the growth curve as described (11) . The growth curves shown in Fig. 2B showed that the doubling times of control GbaSM-4 cells and of MLCK-deficient cells were 2.5 and 1.6 days, respectively, indicating a higher proliferation rate of MLCK-deficient cells. MTT assay reflects the activity of mitochondria, and it could correlate with the cell numbers, as shown in the Fig. 2B inset, when the cytokinesis is intact. In the case where cytokinesis is impaired, the increase in MTT assay product may correlate with the increased number of multi-nucleated cells with increased size. We monitored the multinucleated cells by the TO-PRO-3 staining in our BrdU assay and found no difference between control and MLCKdeficient cells, ruling out the impaired cytokinasis of MLCK-deficient cells. Thus, the MTT assay provides proper assay of the growth curves of control GbaSM-4 and MLCK-deficient cells.
To study the role of MLCK on cell cycle, we further analyzed the cell cycle profile by flow cytometry analysis using propidium iodine staining. More cells within MLCK-deficient cells were at their proliferative states including G2/M and S phases than those of control GbaSM-4 cells (Fig. 2C) . The proliferative index (PI) of GbaSM-4 cells is 36.4%, while that of MLCK-deficient cells is 51.2%. The result of cell cycle analysis is in coincidence with the growth kinetic result obtained by MTT assay (Fig. 2B) .
Our previous experiment in vitro showed that MLCK inhibited the ATPase activity when myosin (smooth muscle myosin II isoform) light chain was phosphorylated; the inhibition was mediated by its N-terminal 1 -41 amino acids (2, 12) . The contractile ring consisting of actin-filaments required myosin phosphorylation to initiate cytokinesis (reviewed in ref. 3) . We used the motility assay, in which actin-filament movement was observed on the glass surface coated with phosphorylated myosin, because it partly works as a model of cytokinesis. In this assay, MLCK exerted an inhibitory effect on the motility through actin-binding activity, that is, through MLCK functions other than kinase activity (reviewed in ref.
2). To observe actual cytokinesis of living cells, we looked for cells that had entered mitosis, and we video-recorded the cells at 10-min intervals. We found that most GbaSM-4 cells underwent slower cytokinesis than MLCK-deficient cells (Fig. 2C) . For example, the upper row of Fig. 2C shows that 70 -80 min was necessary for control GbaSM-4 cells to finish cytokinesis, whereas only 50 min was sufficient for MLCK-deficient cells (lower row). The delayed cell cytokinesis in GbaSM-4 cells should slow down the cell proliferation. According our cell cycle analysis result (Fig. 2C) , the ratio of cells undergoing G1 phase in control GbaSM-4 is 53.4%, but the ratio in MLCK-deficient cells is 42.8%, indicating that the acceleration of cell proliferation might be through shortening the length of the G1 phase.
To elucidate the function of MLCK in cell proliferation, the incorporation of BrdU was examined in a similar way as shown in Fig. 1 . MLCK-deficient cells were rescued by transfecting plasmid vectors conjugated with the following cDNA constructs based on the bovine stomach MLCK sequence (accession number S57131): wild-type (WT) MLCK, kinase-inactive MLCK, or MLCK lacking N-terminal 1 -41 actin-binding site (del 1 -41 MLCK) (Fig. 3) . Kinase-inactive MLCK was constructed by replacing the three Gly in the ATP-binding site of BsMLCK (Gly732, Gly734, and Gly737) with Ala by using the QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) as described in ref. 10 . The construct deleting the actin-binding site was described in ref. 12 . The codon usage of bovine MLCK cDNA is different from that of guinea-pig MLCK cDNA (accession number AB070227). The difference avoids the RNAi-mediated down-regulation of introduced cDNA constructs in MLCK-deficient cells. Also, the difference does not interfere in the expression of the introduced cDNA constructs in cells, as monitored by the expression of Flags tagged to all the constructs (Fig. 3  inset) .
We found significantly higher BrdU incorporation into MLCK-deficient cells than untreated GbaSM-4 cells (Fig. 3) . However, the incorporation of BrdU into the MLCK-deficient cells that were transfected with WT-MLCK construct decreased to a lower level similar to MLCK-deficient cells were loaded to 8% SDS-PAGE followed by immunoblotting using antibody against MLCK, smMHC, and α-SMA. B) The 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma) was used to determine the cell numbers according to the manufacturer's control. The cells were seeded at low density (2 × 10 3 ) in 96-well plates and grown for 7 days and fresh medium was provided everyday. At the end of the indicated time, 10 μL MTT (final concentration 0.5 mg/mL) was added to each well and then incubated at 37°C for 4 h. After removing the medium completely, solubilization solution (10% w/v sodium dodecyl sulfate in 0.01 M HCl) was added at 100 μL/well. After overnight incubation, optical density of each well was determined by an automated dual-wavelength Vmax kinetic microplate reader (Molecular Devices, Downingtown, PA, USA) against a reagent blank (i.e., no cells) at a test wavelength of 570 nm with a reference of 630 nm. The inset is the standard curve to estimate cell numbers as monitored at A570 nm. Growth curves of GbaSM-4 cells and MLCKdeficient cells were plotted by the fold of cell number increase against that of 0.25 day. The data (n = 5) are expressed as means ± S.E.M. C) Cell cycle analysis of GbaSM-4 and MLCK-deficient cells were performed by flow cytometric analysis using propidium iodine staining. Cells were fixed using 70% ice-cold ethanol, followed by propidium iodine (Sigma) staining (50 μg/ mL) in the presence of 50 g/mL RNaseA (Sigma) for 30 min at 37°C in the dark, and resuspension in PBS. Analysis was performed with FACScan (Becton Dickinson, Mountain View, CA, USA). Cell cycle distributions were analyzed by the CELL FIT software package. The proliferation index (PI) was calculated according to the formula: PI = (G2/M + S) / (G1 + S + G2/M) 100%. D) Time-lapse recording of typical cytokinesis of GbaSM-4 cell and MLCK-deficient cell. Scale bar represents 10 μm.
original wild-type GbaSM-4 ( Fig. 3) , as expected from the result of Fig. 1 . MLCK-deficient cells transfected with a kinase-inactive MLCK-construct (i.e., that has an intact actin-binding site) showed BrdU incorporation as low as that of cells transfected with the WT-MLCK construct. On the other hand, we found that the MLCKdeficient cells transfected with a MLCK construct lacking only the actin-binding domain (del 1 -41 MLCK) failed to revert cell proliferation to the low level of wildtype cells (Fig. 3) . Therefore, we interpreted this to mean that actin-binding activity of MLCK plays an important role in decreasing cell proliferation of GbaSM-4.
A conventional explanation on cytokinesis is that MLCK phosphorylates myosin associated with the contractile ring to cause cytokinesis (reviewed in ref. 3) . In MLCK-deficient cells, kinases other than MLCK such as Rho kinase (Fig. 6 in ref. 10 ) may phosphorylate myosin, as discussed previously (13) . Although the studies are in vitro, the actin-binding domain of MLCK exerts an inhibitory effect on the phosphorylated myosin (2, 12) . MLCK, if it were not down-regulated, would have inhibited cytokinesis. As described immediately before this paragraph, however, MLCK was no more persistent in the MLCK-deficient cell as shown in Fig. 2A .
The presence of MLCK in nuclei has been known for years (14) . The presence of actin in nuclei in addition to MLCK was demonstrated by Bachs et al. (15) , and they suggested the possibility that MLCK may regulate transcription. Our data that the nuclei of the GbaSM-4 cells are stained often by the anti-MLCK antibody (data not shown) support this possibility. If so, involvement of the N-terminal domain, not the kinase domain, in the proliferation should be feasible. We proposed here another possibility, that MLCK may regulate cell proliferation via condensation and dispersion of chromatin through actin within the nuclei. To establish these possible functions of MLCK, additional research on MLCK is required. Fig. 3 . Effects of expression of MLCK and its mutants in MLCK-deficient cells on cell proliferation. MLCK-deficient cells were transiently transfected with the indicated plasmids by the use of AMXA nucleofector. The expressions of transfected proteins were confirmed by immunoblotting (top and bottom panels). BrdU incorporation experiment was performed 48 h after transfection as described in Fig. 1 . After incubation with BrdU for 12 h, cells were fixed and stained with an anti-BrdU antibody. The percentage of BrdUpositive cells was calculated over total TO-PRO-3-positive cells. The data are the means ± S.E.M. from three experiments, n = 200 cells. Statistical significance was determined by one-way ANOVA test ( Student-Newman-Keuls Method) using Sigma Stat version 3.1; **P < 0.001 was considered to be statistically significant; n.s. means there is no statistically significant difference.
